# Anticonvulsant Therapy in Trigeminal Neuralgia: A Class-Oriented Systematic Review

## TL;DR

This review compares how well different types of anticonvulsant drugs work for treating trigeminal neuralgia, a painful facial condition.

## Contribution

The study provides a class-based evaluation of anticonvulsants for trigeminal neuralgia, highlighting efficacy and safety differences.

## Key findings

- Sodium channel inhibitors are effective but cause frequent adverse effects like hyponatremia.
- Calcium channel modulators offer better tolerability and safety profiles.
- Combination therapies and drugs like levetiracetam and topiramate show moderate efficacy with good tolerability.

## Abstract

Background/Objectives: Trigeminal Neuralgia (TN) is a chronic neuropathic condition characterized by sudden, severe facial pain. Anticonvulsants are the cornerstone of pharmacological management, yet comparative evidence based on pharmacological class remains scarce. This systematic review aimed to evaluate the efficacy and safety of anticonvulsants in TN, stratified by their mechanism of action. Methods: A systematic search in PubMed, Scopus and Web of Science was conducted following PRISMA 2020 guidelines. Studies employing a pharmacological approach including human patients with TN, published in English since 2000, were included. Risk of bias was assessed using the Cochrane RoB 2, the ROBINS-I and the ROBINS-E tools, according to the study design. Results: Out of 922 initial records, 12 studies met the eligibility criteria. Sodium channel inhibitors showed high efficacy but frequent adverse effects, particularly hyponatremia and central nervous system symptoms. Calcium channel modulators offered a more favorable safety profile. Combination therapies showed benefits, levetiracetam and topiramate were moderately effective and well tolerated. Although the evidence has limitations, anticonvulsants continue to be the primary treatment for TN. Sodium-channel blockers demonstrate strong efficacy, whereas alternative agents generally provide superior tolerability. Conclusions: These findings support selecting drugs according to their underlying mechanisms of action. Equally important is tailoring therapy to pain phenotype and patient characteristics, balancing mechanism with tolerability and efficacy.